That means Lilly must complete an ongoing clinical trial ACHIEVE-4 which is comparing Foundayo to insulin glargine in patients with type 2 diabetes and overweight or obese who are at elevated cardiovascular risk
Last updated: April 2026 Reviewed monthly as formularies and coverage policies change Disclaimer The information on this page is for educational and informational purposes only and is not intended as medical advice
Four physician-guided programs, compounded to your exact prescription.
Tirzepatide, a dual GIP and GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), may indirectly affect menstrual cycles in some women
Notably, GHK-Cu (with some limitations) and L-Theanine have been added to Category 1, making them eligible to use as active ingredients in 503A compounding
Shapely memberships do not include: Medications Labs (typically covered by insurance or $75) Medications we prescribe Prescriptions are at the medical providers discretion and may not be appropriate for everyone